Literature DB >> 11600377

New model of oropharyngeal candidiasis in mice.

Y Kamai1, M Kubota, Y Kamai1, T Hosokawa, T Fukuoka, S G Filler.   

Abstract

We established a straightforward murine model of oropharyngeal candidiasis. Mice were immunosuppressed with cortisone acetate, anesthetized, and then inoculated by placing cotton wool balls saturated with Candida albicans sublingually for 2 h. A prolonged, reproducible infection was induced. This model may be useful for antifungal screening or pathogenesis studies.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11600377      PMCID： PMC90803          DOI： 10.1128/AAC.45.11.3195-3197.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats.

Authors:  A Martinez; J Regadera; E Jimenez; I Santos; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  T J Walsh; C E Gonzalez; S Piscitelli; J D Bacher; J Peter; R Torres; D Shetti; V Katsov; K Kligys; C A Lyman
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  V Petraitis; R Petraitiene; A H Groll; T Sein; R L Schaufele; C A Lyman; A Francesconi; J Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome.

Authors:  R S Klein; C A Harris; C B Small; B Moll; M Lesser; G H Friedland
Journal:  N Engl J Med       Date:  1984-08-09       Impact factor: 91.245

Review 5.  Experimental oral candidiasis in animal models.

Authors:  Y H Samaranayake; L P Samaranayake
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

6.  New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents.

Authors:  A M Flattery; G K Abruzzo; C J Gill; J G Smith; K Bartizal
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

7.  Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance.

Authors:  J A Sangeorzan; S F Bradley; X He; L T Zarins; G L Ridenour; R N Tiballi; C A Kauffman
Journal:  Am J Med       Date:  1994-10       Impact factor: 4.965

Review 8.  Oral candidiasis and human immunodeficiency virus infection.

Authors:  L P Samaranayake; P Holmstrup
Journal:  J Oral Pathol Med       Date:  1989-12       Impact factor: 4.253

9.  Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations.

Authors:  A M Gillum; E Y Tsay; D R Kirsch
Journal:  Mol Gen Genet       Date:  1984
  9 in total
  65 in total

1.  Mouse model of oropharyngeal candidiasis.

Authors:  Norma V Solis; Scott G Filler
Journal:  Nat Protoc       Date:  2012-03-08       Impact factor: 13.491

2.  Contribution of Candida albicans ALS1 to the pathogenesis of experimental oropharyngeal candidiasis.

Authors:  Yasuki Kamai; Mikie Kubota; Yoko Kamai; Tsunemichi Hosokawa; Takashi Fukuoka; Scott G Filler
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

3.  The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.

Authors:  Brad J Spellberg; Ashraf S Ibrahim; Valentina Avenissian; Scott G Filler; Carter L Myers; Yue Fu; John E Edwards
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice.

Authors:  Yasuki Kamai; Masayo Kakuta; Takahiro Shibayama; Takashi Fukuoka; Shogo Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs.

Authors:  Karl V Clemons; Gloria M Gonzalez; Gaurav Singh; Jackie Imai; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

6.  CD4(+)CD25(+)Foxp3(+) regulatory T cells promote Th17 cells in vitro and enhance host resistance in mouse Candida albicans Th17 cell infection model.

Authors:  Pushpa Pandiyan; Heather R Conti; Lixin Zheng; Alanna C Peterson; Douglas R Mathern; Nydiaris Hernández-Santos; Mira Edgerton; Sarah L Gaffen; Michael J Lenardo
Journal:  Immunity       Date:  2011-03-25       Impact factor: 31.745

Review 7.  Host cell invasion by medically important fungi.

Authors:  Donald C Sheppard; Scott G Filler
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

8.  SR-like RNA-binding protein Slr1 affects Candida albicans filamentation and virulence.

Authors:  Chaiyaboot Ariyachet; Norma V Solis; Yaoping Liu; Nemani V Prasadarao; Scott G Filler; Anne E McBride
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

9.  Rapid Phenotypic and Genotypic Diversification After Exposure to the Oral Host Niche in Candida albicans.

Authors:  Anja Forche; Gareth Cromie; Aleeza C Gerstein; Norma V Solis; Tippapha Pisithkul; Waracharee Srifa; Eric Jeffery; Darren Abbey; Scott G Filler; Aimée M Dudley; Judith Berman
Journal:  Genetics       Date:  2018-05-03       Impact factor: 4.562

10.  Host cell invasion and virulence mediated by Candida albicans Ssa1.

Authors:  Jianing N Sun; Norma V Solis; Quynh T Phan; Jashanjot S Bajwa; Helena Kashleva; Angela Thompson; Yaoping Liu; Anna Dongari-Bagtzoglou; Mira Edgerton; Scott G Filler
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.